Tags » Tocilizumab

Stopping DMARDs Often Unnecessary for RA Patients Prior to Orthopaedic Surgery

Most patients with rheumatoid arthritis (RA) will undergo orthopaedic surgery during the course of their disease, and more than 80% of that cohort will be taking traditional or biologic disease-modifying antirheumatic drugs (DMARDs) at the time of their operations. 170 more words

Surgeon Edition

Turbo charge day

I’m not sure how many of you know what it is like to have a chronic disease – what it means to me is a way of life! 731 more words

Tocilizumab is well tolerated in elderly rheumatoid arthritis patients but shows lower efficacy

A relatively new biologic treatment that is approved for treating rheumatoid arthritis is Tocilizumab (trade name Actemra and RoActemra). Tocilizumab is a humanised monoclonal antibody that targets interleukin-6 receptor (IL-6R), thus blocking interleukin-6 (IL-6) cytokine mediated signalling, which is known to play an important role in mediating inflammatory processes. 242 more words


Tocilizumab Impresses in Polyarticular Juvenile Arthritis


Tocilizumab Impresses in Polyarticular Juvenile Arthritis

MADRID, Spain — Children with polyarticular juvenile idiopathic arthritis treated with tocilizumab (Actemra, Genentech) achieved high response rates with sustained improvement in the phase 3 CHERISH trial. 127 more words

Tocilizumab monotherapy versus adalimumab monotherapy for treatment of rheumatoid arthritis (ADACTA): a randomised, double-blind, controlled phase 4 trial.


Roughly a third of patients with rheumatoid arthritis treated with biological treatments receive them as monotherapy. Tocilizumab—an inhibitor of interleukin 6 receptor signalling—has been studied as monotherapy in several… 265 more words


FDA Approves Actemra for Children with Polyarticular Juvenile Idiopathic Arthritis


April 30, 2013

Roche announced today that the U.S. Food and Drug Administration (FDA) has approved Actemra (tocilizumab) for the treatment of polyarticular juvenile idiopathic arthritis (PJIA). 780 more words


Newzealand's PHARMAC is seeking feedback on a proposal to list pegfilgrastim (Neulastim) and tocilizumab (Actemra) , from 1 July 2013, with Roche Products (NZ) Limited.


Tocilizumab and pegfilgrastim

12 April 2013

PHARMAC is seeking feedback on a proposal to list pegfilgrastim (Neulastim) for prevention of neutropenia in patients undergoing cancer chemotherapy, and tocilizumab (Actemra) for systemic juvenile idiopathic arthritis, from 1 July 2013, through a provisional agreement with Roche Products (NZ) Limited. 290 more words